DCS ImmunoLine: p63 [SFI-6] - die kleine Revolution! Jetzt die [Epub ahead of print] aus dem 1. Virchows Arch. 2013 Jul 26. erhĂ¤ltlich!
Characterization of specific p63 and p63-N-terminal isoform antibodies and their application for immunohistochemistry.
Nekulova M, Holcakova J, Nenutil R, Stratmann R, Bouchalova P, MĂĽller P, MoukovĂˇ L, Coates PJ, Vojtesek B.
Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53, Brno, Czech Republic.
The TP63 gene gives rise to protein isoforms with different properties and functions due to the presence (TAp63) or absence (ΔNp63) of an N-terminal p53-like transactivation domain. Immunohistochemistry for p63 has clinical value
for certain tumour types, but investigations have been hampered by a lack of well characterized antibodies and the inability to discriminate between these N-terminal isoforms with opposite functional properties. We have extensively
characterized a series of monoclonal antibodies to recombinant human TAp63 and two commercial p63 monoclonals by Western blot, immunostaining and phage display epitope mapping. Twenty-eight of 29 (96.6 %) novel monoclonals that recognized all p63 isoforms showed substantial cross-reactivity with p73, as did the commercial antibody, 4A4. One novel clone, PANp63-6.1, showed slight cross-reaction with p73 by Western blotting but not immunohistochemistry and the SFI-6 monoclonal did not cross-react with p73 or p53. .....
PMID: 23887585 [PubMed - as supplied by publisher]